Dr. Rawlings’ primary research interests include dysregulated B cell development and signaling leading to immunodeficiency, autoimmunity or lymphoid malignancies, and the development of gene therapy for primary immune deficiency diseases. His laboratory uses expertise in basic and clinical immunology, signal transduction and lymphocyte developmental biology to understand how altered signals can lead to immunologic disease, with the ultimate goal of developing translational therapies capable of specifically modulating these disorders. Dr. Rawlings is a member of multiple regional and national organizations, an NIH study section member, chairman for the USIDNET XLA patient registry, and ad hoc reviewer for various grant programs and immunology journals. He also co-directs the Northwest Genome Engineering Consortium, a research program funded as part of the NIH Roadmap for Medical Research and comprised of seven collaborative projects focused on developing enzymatic reagents and delivery methods for site specific gene repair in hematopoietic stem cells.
